Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Vascular Diseases 1Rectal Neoplasms 1Precancerous Conditions 1Neurotoxicity Syndromes 1Myocardial Ischemia 1Myocardial Infarction 1Heart Diseases 1Fibrosis 1Fatigue 1Erectile Dysfunction 1Coronary Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Cerebrovascular Disorders 1Cardiovascular Diseases 1Brain Neoplasms 1Adenomatous Polyps 1

Interventions

Temozolomide 53Bevacizumab 45Radiotherapy 28Radiosurgery 21Carboplatin 14Erlotinib Hydrochloride 11Radiation 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Etoposide 9Vorinostat 8Trastuzumab 8Irinotecan 8Sunitinib 7Sorafenib 7Radiotherapy, Intensity-Modulated 7Lomustine 7Lapatinib 7Capecitabine 7dabrafenib 6Ipilimumab 6Imatinib Mesylate 6Cyclophosphamide 6Sirolimus 5Hydroxyurea 5Everolimus 5Bortezomib 5temsirolimus 4cabozantinib 4binimetinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Brain Neoplasms × Vitamin E × Clear all
NCT01508221 2023-09-14

Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis

University of Cincinnati

Phase 2 Completed
31 enrolled 8 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡